CYP26A1 and lung cancer: However, both RARβ2 and CYP26A1 (Figure 2A) expression levels in treated MDA-MB-231 cells were relatively low compared to the levels seen in RA-sensitive lung cancer-positive control cells, Calu-6, also treated with 10 μM aRA for 3 days.